BioAgilytix accelerates global expansion with the acquisition of IPM Biotech

BioAgilytix, a provider of contract bioanalytical testing services and large molecule bioanalysis, has acquired IPM Biotech, a German bioanalytical contract research laboratory with a strong focus on immunogenicity.

The transaction not only expands BioAgilytix's global footprint, with IPM's newly planned GLP and GMP laboratory facility, but also brings IPM's rich immunogenicity, pharmacokinetics (PK) and pharmacodynamics (PD) expertise on board to complement BioAgilytix's capabilities in biomarkers, cell-based assays, immunogenicity and pharmacokinetics.

Each company has experienced organic growth by committing to scientific quality and attentive customer service. Together, they will offer this same level of science and service to customers all over the world, with expanded capabilities to support all phases of large molecule global studies.

‘The 20 years of experience that IPM brings in assay development and validation work for immunogenicity, PK and PD is a perfect complement to BioAgilytix's best-of-breed large molecule bioanalytical capabilities,’ said Dr Arno Kromminga, the founder of IPM. ‘As a merged company, we will truly be an advanced contract research laboratory, capable of supporting global studies for any type of large molecule requirement.’

‘Our team is excited to have significantly enhanced our service offering and geographical coverage for our global client base by partnering with IPM Biotech,’ said Jim Datin, Chief Executive Officer of BioAgilytix.

David Belluck, General Partner at Riverside Partners, BioAgilytix's parent company, said: ‘Riverside is thrilled to support the IPM acquisition. The team at BioAgylitix has been investing in world class scientists and new facilities, along with leading platforms and will now be well-equipped to support significant growth in Europe.’